NRC Health is expected to report Q3 2026 revenue of $35.80 million and EPS of $0.21, with its stock currently trading at $20.69 compared to a median analyst price target of $26.00.
Investors are primarily focused on the growth trajectory of Total Recurring Contract Value (TRCV) for the Q3 2026 reporting period.
Management previously indicated that implementation costs for a landmark contract would normalize this quarter, potentially paving the way for EBITDA margin expansion. Additionally, the company is aiming to sustain its double-digit TRCV growth while completing the large-scale deployment of its Human Understanding subscription solutions.